Antiarrhythmic agents in facilitating electrical cardioversion of atrial fibrillation and promoting maintenance of sinus rhythm

Cardiology

Volumn 95, Issue 1, 2001, Pages 1-8

  Marcus, Gregory M ^a   Sung, Ruey J ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antiarrhythmic therapy; Atrial fibrillation; DC cardioversion; Electrical cardioversion; Maintenance of sinus rhythm

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; DISOPYRAMIDE; FLECAINIDE; IBUTILIDE; PROPAFENONE; QUINIDINE; SOTALOL;

CARDIOVERSION; DRUG EFFICACY; DRUG MECHANISM; HEART ATRIUM FIBRILLATION; HEART AUTOMATICITY; HUMAN; IMPEDANCE; PRIORITY JOURNAL; REVIEW; SINUS RHYTHM;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; COMBINED MODALITY THERAPY; ELECTRIC COUNTERSHOCK; HUMANS; RECURRENCE;

EID: 0034985463     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000047335     Document Type: Review

References (69)

1. Management of patients with atrial fibrillation. A Statement for Healthcare Professionals
2. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: The Framingham study
3. Epidemiologic features of chronic atrial fibrillation: The Framingham study
4. Electrophysiologic aspects of human atrial fibrillation
5. New method for terminating cardiac arrhythmias
6. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins
7. Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins: Electrophysiological characteristics, pharmacological responses, and effects of radiofrequency ablation
8. Quantitative assessment of the spatial organization of atrial fibrillation in the intact human heart
9. Length of excitation wave and susceptibility to reentrant atrial arrhythmias in normal conscious dogs
10. Electrophysiologic mechanisms of perpetuation of atrial fibrillation
11. Electrophysiologic studies in atrial fibrillation. Slow conduction of premature impulses: A possible manifestation of the background for reentry
12. Electrophysiological properties in chronic lone atrial fibrillation
13. Mechanism of flecainide's antiarrhythmic action in experimental atrial fibrillation
14. Comparative mechanisms of antiarrhythmic drug action in experimental atrial fibrillation. Importance of use-dependent effects on refractoriness
15. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats
16. Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter
17. Electrical reversion of cardiac arrhythmias
18. Factors influencing long term persistence of sinus rhythm after a first electrical cardioversion for atrial fibrillation
19. Maintenance of sinus rhythm after atrial defibrillation
20. Electrical reversion of atrial fibrillation. Selection of patients in 1971
21. Effect of verapamil and procainamide on atrial fibrillation-induced electrical remodeling in humans
22. Verapamil reduces tachycardia-induced electrical remodeling of the atria
23. Pre-treatment with verapamil in patients with persistent or chronic atrial fibrillation who underwent electrical cardioversion
24. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction
25. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators
26. The Atrial fibrillation follow-up investigation of rhythm management - The AFFIRM study design
27. A randomized comparison of external and internal cardioversion of chronic atrial fibrillation
28. Electrical conversion of atrial fibrillation: Clinical experience in 185 cases with long-term results
29. Factors predicting maintenance of sinus rhythm after direct current cardioversion of atrial fibrillation and flutter: A reanalysis with recently acquired data
30. Arbeitsgemeinschaft leitender kardiologischer krankenhausärzte
31. Doppler echocardiographic parameters predictive of recurrence of atrial fibrillation of different etiologic origins
32. Echocardiographic parameters for predicting maintenance of sinus rhythm after internal atrial defibrillation
33. Atrial enlargement as a consequence of atrial fibrillation. A prospective echocardiographic study
34. Is there a place for the late cardioversion of atrial fibrillation? A long-term follow-up study of patients with post-thyrotoxic atrial fibrillation
35. Direct current cardioversion of established atrial fibrillation
36. Effect of intravenous procainamide on direct-current cardioversion of atrial fibrillation
37. The interaction of antiarrhythmic drugs and the energy for cardioversion of chronic atrial fibrillation
38. Effects of flecainide on the atrial defibrillation threshold
39. Favorable effects of flecainide in transvenous internal cardioversion of atrial fibrillation
40. Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: A placebo-controlled study
41. Amiodarone in restoration and maintenance of sinus rhythm in patients with chronic atrial fibrillation after unsuccessful direct-current cardioversion
42. Effect of parenteral d-sotalol on transvenous atrial defibrillation threshold in a canine model of atrial fibrillation
43. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment
44. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials
45. Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter
46. Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: A randomized, double-blind study
47. Propafenone for conversion and prophylaxis of atrial fibrillation
48. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation
49. Efficacy and safety of sotalol versus quinidine for the maintenance of sinus rhythm after conversion of atrial fibrillation
50. The efficacy of quinidine and disopyramide in the maintenance of sinus rhythm after electroconversion from atrial fibrillation. A double-blind study comparing quinidine, disopyramide and placebo
51. Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrillation. A placebo-controlled one-year follow-up study
52. Flecainide in the prevention of atrial fibrillation after cardioversion: Comparison with quinidine
53. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation
54. Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation
55. Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia
56. Amiodarone: Reevaluation of an old drug
57. Safety and efficacy of amiodarone. The low-dose perspective
58. Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium
59. Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter
60. Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter
61. Amiodarone versus quinidine in the prophylaxis of atrial fibrillation
62. Efficacy of amiodarone for refractory supraventricular tachyarrhythmias
63. Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy
64. Amiodarone for refractory atrial fibrillation
65. Amiodarone in the management of refractory atrial fibrillation
66. Amiodarone to prevent recurrence of atrial fibrillation
67. Chronic atrial fibrillation. Long-term results of direct current conversion
68. Therapy of refractory symptomatic atrial fibrillation and atrial flutter: A staged care approach with new antiarrhythmic drugs
69. Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter